Shares of Fulgent Genetics Inc. (FLGT) are soaring in pre-market trading on Monday, with the stock up 5.46% as of 9:39 AM ET. This significant uptick comes on the heels of a positive analyst report from UBS, reaffirming investor confidence in the genetic testing company.

UBS analyst Lu Li has maintained a Buy rating on Fulgent Genetics, setting a price target of $35.00. This vote of confidence from a major financial institution appears to be driving bullish sentiment among investors. Li, who covers the Healthcare sector, sees potential in Fulgent Genetics' business model and growth prospects, contributing to the stock's impressive pre-market rally.

While specific details of the analyst's rationale were not provided, the maintained Buy rating suggests a positive outlook for Fulgent Genetics in the competitive healthcare sector. Investors are likely interpreting this as a signal of the company's strong market position and potential for future growth, driving the stock's upward momentum as the trading week begins.